Emily A Burger1,2, Kyueun Lee1,3, Mona Saraiya4, Trevor D Thompson4, Harrell W Chesson4, Lauri E Markowitz4, Jane J Kim1. 1. Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts. 2. Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Norway. 3. Department of Health Research and Policy, Stanford University, Stanford, California. 4. Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: In the United States, the burden of human papillomavirus (HPV)-associated cancers varies by racial/ethnic group. HPV vaccination may provide opportunities for primary prevention of these cancers. Herein, the authors projected changes in HPV-associated cancer burden among racial/ethnic groups under various coverage assumptions with the available first-generation and second-generation HPV vaccines to evaluate changes in racial/ethnic disparities. METHODS: Cancer-specific mathematical models simulated the burden of 6 HPV-associated cancers. Model parameters, informed using national registries and epidemiological studies, reflected sex-specific, age-specific, and racial/ethnic-specific heterogeneities in HPV type distribution, cancer incidence, stage of disease at detection, and mortality. Model outcomes included the cumulative lifetime risks of developing and dying of 6 HPV-associated cancers. The level of racial/ethnic disparities was evaluated under each alternative HPV vaccine scenario using several metrics of social group disparity. RESULTS: HPV vaccination is expected to reduce the risks of developing and dying of HPV-associated cancers in all racial/ethnic groups as well as reduce the absolute degree of disparities. However, alternative metrics suggested that relative disparities would persist and in some scenarios worsen. For example, when assuming high uptake with the second-generation HPV vaccine, the lifetime risk of dying of an HPV-associated cancer for males decreased by approximately 60%, yet the relative disparity increased from 3.0 to 3.9. CONCLUSIONS: HPV vaccines are expected to reduce the overall burden of HPV-associated cancers for all racial/ethnic groups and to reduce the absolute disparity gap. However, even with the second-generation vaccine, relative disparities will likely still exist and may widen if the underlying causes of these disparities remain unaddressed. Cancer 2016;122:2057-66.
BACKGROUND: In the United States, the burden of human papillomavirus (HPV)-associated cancers varies by racial/ethnic group. HPV vaccination may provide opportunities for primary prevention of these cancers. Herein, the authors projected changes in HPV-associated cancer burden among racial/ethnic groups under various coverage assumptions with the available first-generation and second-generation HPV vaccines to evaluate changes in racial/ethnic disparities. METHODS:Cancer-specific mathematical models simulated the burden of 6 HPV-associated cancers. Model parameters, informed using national registries and epidemiological studies, reflected sex-specific, age-specific, and racial/ethnic-specific heterogeneities in HPV type distribution, cancer incidence, stage of disease at detection, and mortality. Model outcomes included the cumulative lifetime risks of developing and dying of 6 HPV-associated cancers. The level of racial/ethnic disparities was evaluated under each alternative HPV vaccine scenario using several metrics of social group disparity. RESULTS:HPV vaccination is expected to reduce the risks of developing and dying of HPV-associated cancers in all racial/ethnic groups as well as reduce the absolute degree of disparities. However, alternative metrics suggested that relative disparities would persist and in some scenarios worsen. For example, when assuming high uptake with the second-generation HPV vaccine, the lifetime risk of dying of an HPV-associated cancer for males decreased by approximately 60%, yet the relative disparity increased from 3.0 to 3.9. CONCLUSIONS:HPV vaccines are expected to reduce the overall burden of HPV-associated cancers for all racial/ethnic groups and to reduce the absolute disparity gap. However, even with the second-generation vaccine, relative disparities will likely still exist and may widen if the underlying causes of these disparities remain unaddressed. Cancer 2016;122:2057-66.
Authors: Marc Arbyn; Christine Bergeron; Paul Klinkhamer; Pierre Martin-Hirsch; Albertus G Siebers; Johan Bulten Journal: Obstet Gynecol Date: 2008-01 Impact factor: 7.661
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Sepehr N Tabrizi; Julia M L Brotherton; John M Kaldor; S Rachel Skinner; Bette Liu; Deborah Bateson; Kathleen McNamee; Maria Garefalakis; Samuel Phillips; Eleanor Cummins; Michael Malloy; Suzanne M Garland Journal: Lancet Infect Dis Date: 2014-08-05 Impact factor: 25.071
Authors: Laurie D Elam-Evans; David Yankey; Jenny Jeyarajah; James A Singleton; Robinette C Curtis; Jessica MacNeil; Susan Hariri Journal: MMWR Morb Mortal Wkly Rep Date: 2014-07-25 Impact factor: 17.586
Authors: Julie S Townsend; C Brooke Steele; Nikki Hayes; Achal Bhatt; Angela R Moore Journal: J Womens Health (Larchmt) Date: 2017-03-06 Impact factor: 2.681
Authors: Djin Lai; Julia Bodson; France A Davis; Doriena Lee; Fahina Tavake-Pasi; Edwin Napia; Jeannette Villalta; Valentine Mukundente; Ryan Mooney; Heather Coulter; Louisa A Stark; Ana C Sanchez-Birkhead; Deanna Kepka Journal: J Community Health Date: 2017-04
Authors: Vicki B Benard; Meg Watson; Mona Saraiya; Rhea Harewood; Julie S Townsend; Antoinette M Stroup; Hannah K Weir; Claudia Allemani Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: E E Jedy-Agba; E O Dareng; S N Adebamowo; M Odutola; E A Oga; F Igbinoba; T Otu; E Ezeome; F Bray; R Hassan; C A Adebamowo Journal: Cancer Epidemiol Date: 2016-10-22 Impact factor: 2.984
Authors: Carolann Risley; Mary W Stewart; Kim R Geisinger; Laree M Hiser; Jody C Morgan; Kenyata J Owens; Krishna Ayyalasomayajula; Rhonda M Rives; Ashish Jannela; Dianne E Grunes; Lei Zhang; Mark Schiffman; Nicolas Wentzensen; Megan A Clarke Journal: Prev Med Date: 2021-07-20 Impact factor: 4.018